Tag:
BioDelivery Sciences
Latest Headlines
Latest Headlines
BioDelivery Sciences snags rights to topical gel for diabetes pain
BioDelivery Sciences secured rights from Arcion Therapeutics to commercialize the company's first-of-its-kind topical gel to treat painful diabetic neuropathy.
BioDelivery snaps up mid-stage diabetic pain drug in potential $39.5M-plus pact
BioDelivery Sciences has added to its pipeline of treatments for the pain market, seizing worldwide rights to an experimental topical therapy for painful diabetic neuropathy (PDN) from Arcion Therapeutics.
BioDelivery garners $40M raise for late-stage pain program
Raleigh, NC-based BioDelivery Sciences International has pieced together a $40 million raise from investors, providing the cash needed to wrap a critical late-stage pain therapy program on its way to a planned date with the FDA.
BDSI's addiction oral patch approaches the market
Based on positive results of a pharmacokinetic study, BioDelivery Sciences is planning a second-quarter 2013 submission for marketing approval of its BioErodible MucoAdhesive (BEMA) formulation of buprenorphine and naloxone for the treatment of opioid dependence.
BDSI snags $2.5M milestone from Meda
BioDelivery Sciences International is in line for $2.5 million milestone payment from Meda, as Breakyl got its first regulatory clearance in the E.U.
BDSI gets patent for anti-opioid film
BioDelivery Sciences International has secured a patent for its dissolvable opioid-dependence treatment, and the company is looking to get BEMA Buprenorphine on the market as soon as next year.
Endo grabs BDSI's drug film chronic pain treatment through global license
BioDelivery Sciences International ( $BDSI )'s dissolvable drug delivery film to treat chronic pain from inside the cheek is still under development and endured a recent clinical setback. But it's
BioDelivery Sciences shares spike on $180M pain drug deal with Endo Pharma
BioDelivery Sciences International ( $BDSI ) surged out of penny-stock territory this morning on news of its deal with Endo Pharmaceuticals ( $ENDP ) to partner on a version of the painkiller
MonoSol targets drug film rival's revenue in updated court complaint
Warren, NJ-based MonoSol Rx aims to get compensated after rival BioDelivery Sciences International ( $BDSI ) received $60 million in revenue from drug-delivery tech that is included in a
BioDelivery shares in meltdown after pain drug flunks PhIII placebo study
After the markets closed yesterday BioDelivery Sciences in Raleigh, NC put out a release detailing the late-stage failure of its pain drug, BEMA Buprenorphine. And despite the best efforts of the CEO
